Original Air Date: 09/24/2025
Run Time: 35 Minutes
Download MP3: http://bit.ly/46UPRx6

The New Administration: A Look Behind the Curtain on Health Issues

PCCA’s Washington-based political consultants John Martin and Matt Duckworth will join the September Public Affairs call to provide a Washington update and share insights on the new administration and its impact on compounding.

John Martin, with Capitol Counsel, previously served at the FDA during the first Trump administration. Matt Duckworth, with Hart Health Strategies, has long worked with PCCA in Washington and will join us at ThinkNext: PCCA International Seminar, October 9-11, 2025, in Houston, Texas.
Did you miss the Alliance for Pharmacy Compounding’s Compounders on Capitol Hill last week?

We’ll discuss need-to-know information from Compounders on Capitol Hill (CCH). Matt Martin will share the latest on the threat to compounded thyroid access, including a letter circulating for lawmaker signatures to FDA led by Rep. Diana Harshbarger (R-TN-1).

Do you compound thyroid medications for your patients?
Urge your lawmaker to sign the letter supporting compounded thyroid access!

Not sure who your lawmaker is? Use this link and type in your zip code.
Select your lawmaker's name to be directed to their website.
Scroll down and locate the Washington, D.C., office phone number.
Call the number, ask to speak with the Health Assistant and request that your lawmaker co-sign Rep. Diana Harshbarger’s letter. The top-line message is that if thyroid is classified as a biologic, as proposed by FDA, then it will be unlawful to compound. Classifying it as a drug will allow continued access — as has been the case for 100+ years.